+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Inhibition of interleukin-1 (alpha and beta), interleukin-2 secretion and surface expression of interleukin-2 receptor (IL-2R) by a novel cytokine interleukin-1 receptor antagonist (IL-1ra)



Inhibition of interleukin-1 (alpha and beta), interleukin-2 secretion and surface expression of interleukin-2 receptor (IL-2R) by a novel cytokine interleukin-1 receptor antagonist (IL-1ra)



Scandinavian Journal of Immunology 36(1): 27-33



IL-1 is a mediator of the acute inflammatory response and plays a key role in influencing growth and differentiation of immunocompetent lymphocytes. It can enhance transcription and secretion of the T-cell growth factor interleukin-2 (IL-2) and can stimulate the expression of membrane receptors for IL-2. However, the regulation and control of IL-1 activities are poorly understood. Recently an IL-1 inhibitor, interleukin-1 receptor antagonist (IL-1ra), has been described and cloned. This protein is a monokine originally found in the urine of febrile patients and in supernatants of human monocytes adhering to an IgG-coated surface, with an approximate molecular weight of 17 kDa, which is similar to IL-1 beta but having no IL-1-like activity and antagonizing IL-1 by binding to its cell surface receptor. These studies have examined some biological properties of hrIL-1ra, such as its effects on the secretion of IL-1 alpha or IL-1 beta and IL-2, the surface expression of IL-2R and DNA synthesis by peripheral blood mononuclear cells (PBMC). PBMC from normal volunteers were separated and used at a concentration of 2.5 x 10(6) cells/ml. The cells were pretreated for 2 h with hrIL-1ra (0.025-250 ng/ml), treated with LPS (10 ng/ml), and IL-1 alpha and IL-1 beta secretion were determined by an ELISA method. In addition the influence of hrIL-1ra (25 ng/ml) on IL-2 generation was determined. In another set of experiments, flow cytometric analysis with an anti-CD25 monoclonal antibody was determined on PHA-stimulated PBMC pretreated with hrIL-1ra (2 h) and cultured for 48 h. The inhibition by hrIL-1ra of IL-2R expression was dose-dependent and when hrIL-1ra was used at 250 ng/ml the IL-2R was completely abolished. Lymphocyte DNA synthesis calculated from the net uptake of [3H]-thymidine (3H-TdR) was also inhibited by hrIL-1ra (0.025-25 ng/ml). In this report we found that hrIL-1ra inhibits, in a dose-dependent manner, the secretion of IL-1 alpha, IL-1 beta, IL-2, the surface expression of IL-2R and 3H-TdR incorporation in PBMC in vitro. These data suggest a new biological activity of hrIL-1ra and further extend the immunomodulatory potential and significance of this new cytokine. The action of IL-1ra on modulating the synthesis of IL-1 may be of paramount importance in the regulation of these effects.

(PDF emailed within 1 workday: $29.90)

Accession: 040446530

Download citation: RISBibTeXText

PMID: 1535451


Related references

Inhibition of Interleukin-1 (Alpha and Beta), Interleukin-2 Secretion and Surface Expression of Interleukin-2 Receptor (IL-2R) by a Novel Cytokine Interleukin-1 Receptor Antagonist (IL-lra). Scandinavian Journal of Immunology 36(1): 27-34, 1992

Inhibition of interleukin-1 beta mRNA expression and interleukin-1 alpha and beta secretion by a specific human recombinant interleukin-1 receptor antagonist in human peripheral blood mononuclear cells. Immunology 77(2): 245-250, 1992

Interleukin-1 alpha and interleukin-1 beta stimulate adrenocorticotropin secretion in the rat through a similar hypothalamic receptor(s): effects of interleukin-1 receptor antagonist protein. Neuroendocrinology 57(1): 14-22, 1993

Expression of interleukin-1 alpha, interleukin-1 beta, and an interleukin-1 receptor antagonist in human retinal pigment epithelial cells. Experimental Eye Research 55(2): 325-335, 1992

Expression of interleukin 1 alpha, interleukin 1 beta and interleukin 1 receptor antagonist mRNA in mouse brain: regulation by bacterial lipopolysaccharide (LPS) treatment. Brain Research. Molecular Brain Research 31(1-2): 122-130, 1995

Interleukin 1 alpha induced interleukin 1 beta and tumor necrosis factor alpha and inhibition by interleukin 1 receptor antagonist. American Review of Respiratory Disease 145(4 PART 2): A270, 1992

Interleukin 1-beta, interleukin 1 receptor antagonist, interleukin 10, and interleukin 13 gene expression in the central nervous system and anterior pituitary during systemic inflammation Pathophysiological implications. Journal of Investigative Medicine 45(3): 238A, 1997

Polymorphisms in lymphotoxin alpha and interleukin-1 receptor antagonist genes and secretion of tumour necrosis factor alpha, soluble interleukin-2 receptor and interleukin 6 in Chinese patients with inflammatory bowel disease. Gastroenterology 114(4 PART 2): A1117, April 15, 1998

Interleukin-1 beta, interleukin-1 receptor antagonist, and soluble interleukin-1 receptor type II secretion in chronic fatigue syndrome. Journal of Clinical Immunology 17(3): 253-261, 1997

Relation of polymorphism of lymphotoxin alpha and interleukin 1 receptor antagonist genes to secretion of tumour necrosis factor alpha, soluble interleukin 2 receptor and interleukin 6 in Chinese patients with inflammatory bowel disease. Acta Academiae Medicinae Hubei 18(3): 209-213, 1997

Cytokine responses to intraventricular injection of interleukin 2 into patients with leptomeningeal carcinomatosis rapid induction of tumor necrosis factor alpha interleukin 1 beta interleukin 6 gamma interferon and soluble interleukin 2 receptor m r 55000 protein. Cancer Research 52(5): 1123-1128, 1992

Interleukin-8 secretion and 15-lipoxygenase activity in rheumatoid arthritis: in vitro anti-inflammatory effects by interleukin-4 and interleukin-10, but not by interleukin-1 receptor antagonist protein. British Journal of Rheumatology 33(6): 520-525, 1994

Interleukin-8 Secretion And 15-Lipoxygenase Acuvtty In Rheumatoid Arthritis: In Vitro Anti-Inflammatory Effects By Interleukin-4 And Interleukin-10, But Not By Interleukin-1 Receptor Antagonist Protein. Rheumatology 33(6): 520-525, 1994

Different pattern of interleukin-1 beta-(IL-1 beta), interleukin-1 receptor antagonist- (IL-1ra) and interleukin-1 receptor type I- (IL-1R tI) mRNA-expression in single preimplantation mouse embryos at various developmental stages. Journal of Reproductive Immunology 34(2): 103-120, 1997

Interleukin-1 beta, interleukin-1 receptor antagonist and interleukin-6 plasma levels and cytokine gene polymorphisms in chronic lymphocytic leukemia: correlation with prognostic parameters. Haematologica 85(6): 600-606, 2000